Cullinan Therapeutics (CGEM) Form 3: Director Reports No Holdings

Doyle Mittie, listed with an address at Cullinan Therapeutics, Inc., One Main Street, Cambridge, MA, filed an initial Form 3 disclosing his relationship to the issuer as a Director.

Rhea-AI Filing Summary

Doyle Mittie, listed with an address at Cullinan Therapeutics, Inc., One Main Street, Cambridge, MA, filed an initial Form 3 disclosing his relationship to the issuer as a Director. The filing, reporting the event date 08/07/2025, states explicitly that no securities are beneficially owned by the reporting person. The signature block shows the form was signed by Jacquelyn Sumer, Attorney-in-Fact on 08/08/2025. This is an initial ownership disclosure required under Section 16 and indicates the reporting person holds no reportable equity in Cullinan Therapeutics, Inc. (CGEM) as of the reported date.

Positive

• Doyle Mittie is disclosed as a Director of Cullinan Therapeutics, showing governance role
• Form 3 explicitly states no securities are beneficially owned as of 08/07/2025

Negative

• None.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Form 3 filed for Cullinan Therapeutics (CGEM) disclose?

The Form 3 discloses that Doyle Mittie, a Director, reported no beneficial ownership of securities in Cullinan Therapeutics as of 08/07/2025.

When was the event requiring the Form 3 filed for CGEM?

The date of the event requiring the statement is 08/07/2025, and the form was signed on 08/08/2025 by an attorney-in-fact.

Who signed the Form 3 for Cullinan Therapeutics (CGEM)?

The signature block shows /s/ Jacquelyn Sumer, Attorney-in-Fact with a signature date of 08/08/2025.

Does the filing list any securities owned by the reporting person?

No. The filing contains the explicit statement: No securities are beneficially owned.

What is the reporting person’s address on the Form 3?

The address shown is Cullinan Therapeutics, Inc., One Main Street, Suite 1350, Cambridge, MA 02142.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/08/2025 - 05:30 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Doyle Mittie

(Last) (First) (Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/07/2025

3. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Jacquelyn Sumer, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.